Clinical update: Novel targets in multiple myeloma

Seminars in Oncology

Volumn 31, Issue SUPPL. 16, 2004, Pages 27-32

  Anderson, Kenneth C ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ALKYLATING AGENT; ANTHRACYCLINE; BORTEZOMIB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IMMUNOMODULATING AGENT; LENALIDOMIDE; MELPHALAN; PREDNISONE; PROTEASOME INHIBITOR; THALIDOMIDE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; BONE MARROW; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MODEL; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CELL INTERACTION; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DISEASE COURSE; DOWN REGULATION; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; DRUG SCREENING; DRUG TARGETING; HUMAN; IMMUNITY; LABORATORY; MALIGNANT NEOPLASTIC DISEASE; METHODOLOGY; MORBIDITY; MULTIPLE MYELOMA; MYELOMA CELL; NEUROPATHY; OUTCOMES RESEARCH; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; THROMBOCYTOPENIA;

EID: 12844281836     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.10.016     Document Type: Article

References (34)

1. American Cancer Society Cancer Facts and Figures 2004 Available at: http://www.cancer.org/docroot/STT/stt_0.asp (accessed February 5, 2004)
2. R.T. Greenlee, M.B. Hill-Harmon, T. Murray Cancer statistics, 2001 CA Cancer J Clin 51 2001 15 36
3. J.R. Berenson, H.M. Ma, R. Vescio The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma Semin Oncol 28 2001 626 633
4. National Cancer Institute: Multiple myeloma and other plasma cell neoplasms. Available at: http://www.cancer.gov/templates/page_print.aspx?viewid= 28de4846-26d4-412f-91d9-167000cdcc49&version=healthprofessional (accessed February 5, 2004)
5. Durie BGM: International Myeloma Foundation. Concise review of the disease and treatment options. Available at: http://myeloma.org/myeloma/ kb_index.jsp?type=detail&id=50 (accessed February 5, 2004)
6. M.A. Hussein Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma Oncologist 7 suppl 1 2002 20 29
7. S. Zweegman, P.C. Huijgens Treatment of myeloma Recent developments Anticancer Drugs 13 2002 339 351
8. L.G. Corral, P.A. Haslett, G.W. Muller Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha J Immunol 163 1999 380 386
9. T. Hideshima, D. Chauhan, Y. Shima Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 96 2000 2943 2950
10. N. Mitsiades, C.S. Mitsiades, V. Poulaki Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells Therapeutic implications Blood 99 2002 4525 4530
11. M.A. Frassanito, A. Cusmai, G. Iodice Autocrine interleukin-6 production and highly malignant multiple myeloma Relation with resistance to drug-induced apoptosis Blood 97 1999 483 489
12. K. Podar, Y.T. Tai, F.E. Davies Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration Blood 98 2001 428 435
13. C. Menetrier-Caux, G. Montmain, M.C. Dieu Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells Role of interleukin-6 and macrophage colony-stimulating factor Blood 92 1998 4778 4791
14. J.E. Ohm, M.R. Shurin, C. Esche Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo J Immunol 163 1999 3260 3268
15. F.E. Davies, N. Raje, T. Hideshima Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma Blood 98 2001 210 216
16. R. LeBlanc, T. Hideshima, L.P. Catley Immunomodulatory drug (Revamid) costimulates T cells via the B7-CD28 pathway Blood 103 2004 1787 1790
17. P.G. Richardson, R.L. Schlossman, E. Weller Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma Blood 100 2002 3063 3067
18. P.G. Richardson, S. Jagannath, R. Schlossman A multi-center, randomized, phase 2 study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone (Dex) for the treatment of relapsed or refractory multiple myeloma (MM) Blood 102 11 2003 235a
19. T. Hideshima, D. Chauhan, T. Hayashi Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma Oncogene 22 2003 8386 8393
20. T. Hideshima, C. Mitsiades, M. Akiyama Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341 Blood 101 2003 1530 1534
21. D. Chauhan, G. Li, T. Hideshima JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells J Biol Chem 278 2003 17593 17596
22. C. Tournier, P. Hess, D.D. Yang Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway Science 288 2000 870 874
23. T. Fotsis, Y. Zhang, M.S. Pepper The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth Nature 368 1994 237 239
24. D. Chauhan, L. Catley, T. Hideshima 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells Blood 100 2002 2187 2194
25. D. Chauhan, T. Hideshima, S. Rosen Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells J Biol Chem 276 2001 24453 24456
26. D. Chauhan, G. Li, M. Sattler Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells Oncogene 22 2003 6296 6300
27. J. Adams Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer Curr Opin Chem Biol 6 2002 493 500
28. R.Z. Orlowski, T.E. Stinchcombe, B.S. Mitchell Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies J Clin Oncol 20 2002 4420 4427
29. P.G. Richardson, B. Barlogie, J. Berenson A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2003 2609 2617
30. European Group for Blood and Marrow Transplant Myeloma Subcommittee of the EBMT J. Bladé, D. Samson, D. Reece Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation Br J Haematol 102 1998 1115 1123
31. C. Seong, K. Delasalle, K. Hayes Prognostic value of cytogenetics in multiple myeloma Br J Haematol 101 1998 1891 1894
32. J.R. Berenson, S. Jagannath, B. Barlogie Experience with long-term therapy using the proteasome inhibitor, bortezomib, in advanced multiple myeloma (MM) Proc Am Soc Clin Oncol 22 2003 581 (abstr 2337)
33. S. Jagannath, B. Barlogie, J. Berenson A phase II multicenter randomized study of the proteasome inhibitor bortezomib (VELCADE, formerly PS-341) in multiple myeloma (MM) patients (pts) relapsed after front-line therapy Blood 100 2002 812a (abstr 3207)
34. P.G. Richardson, P. Sonneveld, M.W. Schuster Bortezomib vs. dexamethasone in relapsed multiple myeloma A phase 3 randomized study Proc Am Soc Clin Oncol 23 2004 558 (abstr 6511)